Ruochan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruochan Chen has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Ju Zou
Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China
15 shared publicationsJie Li
Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China
9 shared publications- Daolin Tang
Department of Surgery, UT Southwestern Medical Center, Dallas, USA
7 shared publications Rui Kang
Department of Surgery, UT Southwestern Medical Center, Dallas, USA
7 shared publicationsXiao Zhong
Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China
7 shared publicationsJiao Liu
DAMP Laboratory, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
5 shared publications
Latest Publications
- 12 August 2026
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 33 (8) , 1131-1146
Structural and molecular principles of DAMP biology
- 12 August 2026
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 33 (8) , 1131-1146
Structural and molecular principles of DAMP biology
- Open Access
- 1 August 2026
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-19
Global Burden of Tuberculosis and Drug-Resistant Subtypes Among Women of Childbearing Age from 1990 to 2021, with Projections to 2030
Background: Tuberculosis (TB) poses a major threat to women of childbearing age (WCBA, 15– 49 years), yet comprehensive global burden analyses remain limited. This study provides a comprehensive global spatiotemporal analysis of TB and drug-resistant subtypes among WCBA. Methods: Using Global Burden of Disease Study 2021 data, we assessed the global incidence and disability-adjusted life years (DALYs) of TB and drug-resistant subtypes among WCBA from 1990 to 2021, and projected trends to 2030 using Bayesian age-period-cohort models. Results: In 2021, an estimated 1.99 million WCBA developed TB globally. The age-standardized incidence rate (ASIR) and age-standardized DALY rate (ASDR) declined for overall TB and drug-susceptible TB (DS-TB), but increased for multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). The large relative increases in XDR-TB should be interpreted cautiously because baseline estimates were very small and case definitions, testing capacity, and surveillance changed over time. The TB burden showed substantial geographic heterogeneity, with the highest age-standardized rates concentrated in Sub-Saharan Africa. Age-specific patterns showed higher ASIRs in younger populations, whereas ASDRs increased with age. Among the four GBD-attributable exposures included in the comparative analysis, high body-mass index had the largest modeled TB-related DALY rate in 2021. This restricted comparison should not be interpreted as ranking all established TB determinants. Projections suggest that overall TB incidence will decline, whereas the modeled XDR-TB ASIR may continue to rise through 2030 globally. Conclusion: Reducing TB among WCBA requires improved access to rapid diagnosis, drug susceptibility testing, effective DR-TB treatment, and risk-based TB screening within reproductive and antenatal care, particularly in low-SDI and high-burden settings. Pregnancy- and postpartum-specific surveillance should also be strengthened, as these populations are not separately identifiable in GBD 2021.
- 1 August 2026
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-19
Open AccessGlobal Burden of Tuberculosis and Drug-Resistant Subtypes Among Women of Childbearing Age from 1990 to 2021, with Projections to 2030
Background: Tuberculosis (TB) poses a major threat to women of childbearing age (WCBA, 15– 49 years), yet comprehensive global burden analyses remain limited. This study provides a comprehensive global spatiotemporal analysis of TB and drug-resistant subtypes among WCBA. Methods: Using Global Burden of Disease Study 2021 data, we assessed the global incidence and disability-adjusted life years (DALYs) of TB and drug-resistant subtypes among WCBA from 1990 to 2021, and projected trends to 2030 using Bayesian age-period-cohort models. Results: In 2021, an estimated 1.99 million WCBA developed TB globally. The age-standardized incidence rate (ASIR) and age-standardized DALY rate (ASDR) declined for overall TB and drug-susceptible TB (DS-TB), but increased for multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). The large relative increases in XDR-TB should be interpreted cautiously because baseline estimates were very small and case definitions, testing capacity, and surveillance changed over time. The TB burden showed substantial geographic heterogeneity, with the highest age-standardized rates concentrated in Sub-Saharan Africa. Age-specific patterns showed higher ASIRs in younger populations, whereas ASDRs increased with age. Among the four GBD-attributable exposures included in the comparative analysis, high body-mass index had the largest modeled TB-related DALY rate in 2021. This restricted comparison should not be interpreted as ranking all established TB determinants. Projections suggest that overall TB incidence will decline, whereas the modeled XDR-TB ASIR may continue to rise through 2030 globally. Conclusion: Reducing TB among WCBA requires improved access to rapid diagnosis, drug susceptibility testing, effective DR-TB treatment, and risk-based TB screening within reproductive and antenatal care, particularly in low-SDI and high-burden settings. Pregnancy- and postpartum-specific surveillance should also be strengthened, as these populations are not separately identifiable in GBD 2021.
- Open Access
Trends in Influenza-Associated Lower Respiratory Tract Infection Burden and Influenza Vaccination Coverage among Adults Aged ≥55 Years in China, 1990–2023
Background: Influenza-associated lower respiratory tract infections (LRTI) impose substantial disease burden on older populations globally. While China has experienced rapid aging, comprehensive assessment of long-term trends in influenza-associated LRTI burden and vaccination coverage among adults aged ≥55 years remains limited. Methods: We extracted age-standardized mortality and disability-adjusted life years (DALYs) rates of influenza-associated LRTI among Chinese adults aged ≥55 years from the Global Burden of Disease Study 2023 (GBD 2023). Estimated annual percentage change (EAPC) and age-period-cohort (APC) models were employed to analyze long-term trends (1990–2023). Using the China Health and Retirement Longitudinal Study 2020 (CHARLS 2020, n=13,815), we performed multivariable logistic regression to identify factors associated with influenza vaccination uptake. Spearman correlation assessed ecological associations between GBD age-specific mortality rates and CHARLS vaccination coverage across nine age groups. Results: Age-standardized mortality rates declined from 4.09 to 0.31 per 100,000 (EAPC=-8.02%, 95%CI: −9.08% to −6.95%), and DALYs rates from 177.63 to 6.06 per 100,000 (EAPC=-10.67%), representing >96% reductions from 1990 to 2023. Deaths dropped sharply by 59.6% in 2020, consistent with protective effects of non-pharmaceutical interventions during COVID-19. The ≥85-year age group showed the slowest improvement (EAPC=-5.63%). Influenza vaccination coverage in CHARLS 2020 was only 15.1%. Older age (≥85 years: OR=0.65, 95%CI: 0.46–0.92) and higher educational attainment (college or above: OR=0.34, 95%CI: 0.20–0.56) were independently associated with lower vaccination rates, though the small sample size in the highest education group (n=68) warrants cautious interpretation. Ecological analysis revealed a significant negative correlation between GBD mortality rates and CHARLS vaccination coverage (r=-0.700, p=0.036, n=9 age groups), indicating a “protection mismatch” phenomenon. Raising vaccination coverage to 75% (WHO target) could prevent approximately 2,041 deaths annually under moderate vaccine efficacy assumptions, with ≥75-year-olds contributing 82.7% of preventable deaths. Conclusions: Influenza-associated LRTI burden has declined substantially among Chinese adults aged ≥55 years, but improvement is slowest in the oldest age groups. Vaccination coverage remains critically insufficient with a persistent “protection mismatch” where those at highest mortality risk have lowest coverage. Adults aged ≥75 years face a “triple vulnerability” of high mortality, low vaccination coverage, and high COPD comorbidity prevalence, and should be prioritized for vaccination to maximize preventable mortality benefits.
Open AccessTrends in Influenza-Associated Lower Respiratory Tract Infection Burden and Influenza Vaccination Coverage among Adults Aged ≥55 Years in China, 1990–2023
Background: Influenza-associated lower respiratory tract infections (LRTI) impose substantial disease burden on older populations globally. While China has experienced rapid aging, comprehensive assessment of long-term trends in influenza-associated LRTI burden and vaccination coverage among adults aged ≥55 years remains limited. Methods: We extracted age-standardized mortality and disability-adjusted life years (DALYs) rates of influenza-associated LRTI among Chinese adults aged ≥55 years from the Global Burden of Disease Study 2023 (GBD 2023). Estimated annual percentage change (EAPC) and age-period-cohort (APC) models were employed to analyze long-term trends (1990–2023). Using the China Health and Retirement Longitudinal Study 2020 (CHARLS 2020, n=13,815), we performed multivariable logistic regression to identify factors associated with influenza vaccination uptake. Spearman correlation assessed ecological associations between GBD age-specific mortality rates and CHARLS vaccination coverage across nine age groups. Results: Age-standardized mortality rates declined from 4.09 to 0.31 per 100,000 (EAPC=-8.02%, 95%CI: −9.08% to −6.95%), and DALYs rates from 177.63 to 6.06 per 100,000 (EAPC=-10.67%), representing >96% reductions from 1990 to 2023. Deaths dropped sharply by 59.6% in 2020, consistent with protective effects of non-pharmaceutical interventions during COVID-19. The ≥85-year age group showed the slowest improvement (EAPC=-5.63%). Influenza vaccination coverage in CHARLS 2020 was only 15.1%. Older age (≥85 years: OR=0.65, 95%CI: 0.46–0.92) and higher educational attainment (college or above: OR=0.34, 95%CI: 0.20–0.56) were independently associated with lower vaccination rates, though the small sample size in the highest education group (n=68) warrants cautious interpretation. Ecological analysis revealed a significant negative correlation between GBD mortality rates and CHARLS vaccination coverage (r=-0.700, p=0.036, n=9 age groups), indicating a “protection mismatch” phenomenon. Raising vaccination coverage to 75% (WHO target) could prevent approximately 2,041 deaths annually under moderate vaccine efficacy assumptions, with ≥75-year-olds contributing 82.7% of preventable deaths. Conclusions: Influenza-associated LRTI burden has declined substantially among Chinese adults aged ≥55 years, but improvement is slowest in the oldest age groups. Vaccination coverage remains critically insufficient with a persistent “protection mismatch” where those at highest mortality risk have lowest coverage. Adults aged ≥75 years face a “triple vulnerability” of high mortality, low vaccination coverage, and high COPD comorbidity prevalence, and should be prioritized for vaccination to maximize preventable mortality benefits.
- 1 July 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (5) , 882-898
Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44+pDC crosstalk
- 1 July 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (5) , 882-898
Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44+pDC crosstalk
- Open Access
- 29 October 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 85, 469-479
Development and validation of an early diagnostic model to distinguish bacterial infection in patients with acute-on-chronic liver disease (AoCLD) and systemic inflammatory response syndrome (SIRS): a post-hoc analysis of a prospective multicenter cohort
- 29 October 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 85, 469-479
Open AccessDevelopment and validation of an early diagnostic model to distinguish bacterial infection in patients with acute-on-chronic liver disease (AoCLD) and systemic inflammatory response syndrome (SIRS): a post-hoc analysis of a prospective multicenter cohort
- 28 October 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (1) , 202-203
Author Response to “Letter to the Editor”: “Critical flaws in the predictive model for bacterial infections in older AoCLD patients”
- 28 October 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (1) , 202-203
Author Response to “Letter to the Editor”: “Critical flaws in the predictive model for bacterial infections in older AoCLD patients”
- Top Cited Papers
- 16 October 2025
- Published by Elsevier in Molecular Cell
- Vol. 85 (20) , 3874-3889
DAMPs in the immunogenicity of cell death
- 16 October 2025
- Published by Elsevier in Molecular Cell
- Vol. 85 (20) , 3874-3889
Top Cited PapersDAMPs in the immunogenicity of cell death
- Open Access
- 31 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 83, 183-218
DAMP signaling networks: from receptors to diverse pathophysiological functions
- 31 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 83, 183-218
Open AccessDAMP signaling networks: from receptors to diverse pathophysiological functions
- 28 July 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (5) , 1133-1150
Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospective cohort study
Objective We aimed to develop an effective model to identify the risk of concurrent bacterial infections in older patients with acute-on-chronic liver disease (AoCLD). Methods Data from 809 individuals aged 60–80 sourced from the CATCH-LIFE cohort were analyzed. Participants were randomly assigned to training and internal validation groups at a ratio of 7:3. An independent cohort of 336 older inpatients with AoCLD from Xiangya Hospital, Central South University was used to conduct an external validation of the model. Independent risk factors were identified using LASSO and logistic regression analysis in the training cohort and were subsequently used to develop a user-friendly model. Model performance was evaluated using area under the curve (AUC), calibration plots, and decision curve analysis in the internal and external validation cohorts. Two different cutoff values were determined to stratify infection risk in older patients with AoCLD. Results The infection rate among older patients with AoCLD was 30.28%. Pulmonary infections were predominant, accounting for 93% of all infections. Gram-negative bacteria were the most frequently isolated pathogens, representing 64% of cases in this population. The novel model developed to identify bacterial infections included three variables: cirrhosis, absolute neutrophil count, and C-reactive protein (CRP) level. The AUC for the training, internal, and external validation datasets demonstrated high accuracy in identifying bacterial infections (AUC of the training dataset = 0.805, AUC of the internal validation dataset = 0.848, and AUC of the external validation dataset = 0.838). The model significantly outperformed neutrophil count, CRP level, and procalcitonin level alone in detecting bacterial infections among older patients with AoCLD. To facilitate clinical decision-making, we defined two cutoff values of prediction probability: a low cutoff of 32.2% to rule out bacterial infections and a high cutoff of 47.9% to confidently confirm bacterial infections. Conclusion Our model aids in the early and precise diagnosis of bacterial infections in older patients with AoCLD, thereby facilitating prompt interventions to prevent adverse outcomes. Graphical abstract
- 28 July 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (5) , 1133-1150
Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospective cohort study
Objective We aimed to develop an effective model to identify the risk of concurrent bacterial infections in older patients with acute-on-chronic liver disease (AoCLD). Methods Data from 809 individuals aged 60–80 sourced from the CATCH-LIFE cohort were analyzed. Participants were randomly assigned to training and internal validation groups at a ratio of 7:3. An independent cohort of 336 older inpatients with AoCLD from Xiangya Hospital, Central South University was used to conduct an external validation of the model. Independent risk factors were identified using LASSO and logistic regression analysis in the training cohort and were subsequently used to develop a user-friendly model. Model performance was evaluated using area under the curve (AUC), calibration plots, and decision curve analysis in the internal and external validation cohorts. Two different cutoff values were determined to stratify infection risk in older patients with AoCLD. Results The infection rate among older patients with AoCLD was 30.28%. Pulmonary infections were predominant, accounting for 93% of all infections. Gram-negative bacteria were the most frequently isolated pathogens, representing 64% of cases in this population. The novel model developed to identify bacterial infections included three variables: cirrhosis, absolute neutrophil count, and C-reactive protein (CRP) level. The AUC for the training, internal, and external validation datasets demonstrated high accuracy in identifying bacterial infections (AUC of the training dataset = 0.805, AUC of the internal validation dataset = 0.848, and AUC of the external validation dataset = 0.838). The model significantly outperformed neutrophil count, CRP level, and procalcitonin level alone in detecting bacterial infections among older patients with AoCLD. To facilitate clinical decision-making, we defined two cutoff values of prediction probability: a low cutoff of 32.2% to rule out bacterial infections and a high cutoff of 47.9% to confidently confirm bacterial infections. Conclusion Our model aids in the early and precise diagnosis of bacterial infections in older patients with AoCLD, thereby facilitating prompt interventions to prevent adverse outcomes. Graphical abstract
- Top Cited PapersOpen Access
- 11 July 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-53
Pattern recognition receptors: function, regulation and therapeutic potential
Pattern recognition receptors (PRRs) are sensors in the immune system, detecting pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). They serve as essential links between the innate and adaptive immune responses, initiating defense mechanisms against pathogens and maintaining immune homeostasis. This review examines the classification, structure, and signaling cascades of key PRR families, including toll-like receptors (TLRs), C-type lectin receptors (CLRs), nucleotide-binding oligomerization domain-like receptors (NLRs), AIM2-like receptors (ALRs), and others. It explores the dual roles of PRRs in immune defense and regulation, particularly through inhibitory PRRs (iPRRs), which prevent immune overactivation. The review also investigates the ligand recognition mechanisms and signaling pathways, highlighting the involvement of PRRs in disease progression and immune modulation. Notable signaling pathways, including NF-κB, MAPK, cGAS-STING, and MYD88-mediated and non-MYD88-mediated cascades, are discussed in the context of immune responses. Mechanisms that fine-tune PRR-mediated responses include transcriptional and fpost-transcriptional regulation, protein degradation, subcellular localization, and the recruitment of amplifiers and inhibitors, along with metabolic and microbial factors. These regulatory strategies ensure immune signaling remains adaptable and precise, preventing excessive inflammation. The review also explores the therapeutic potential of targeting PRRs in treating infectious, inflammatory, autoimmune, and malignant diseases, underscoring their importance in advancing immunological research and precision medicine.
- 11 July 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-53
Top Cited PapersOpen AccessPattern recognition receptors: function, regulation and therapeutic potential
Pattern recognition receptors (PRRs) are sensors in the immune system, detecting pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). They serve as essential links between the innate and adaptive immune responses, initiating defense mechanisms against pathogens and maintaining immune homeostasis. This review examines the classification, structure, and signaling cascades of key PRR families, including toll-like receptors (TLRs), C-type lectin receptors (CLRs), nucleotide-binding oligomerization domain-like receptors (NLRs), AIM2-like receptors (ALRs), and others. It explores the dual roles of PRRs in immune defense and regulation, particularly through inhibitory PRRs (iPRRs), which prevent immune overactivation. The review also investigates the ligand recognition mechanisms and signaling pathways, highlighting the involvement of PRRs in disease progression and immune modulation. Notable signaling pathways, including NF-κB, MAPK, cGAS-STING, and MYD88-mediated and non-MYD88-mediated cascades, are discussed in the context of immune responses. Mechanisms that fine-tune PRR-mediated responses include transcriptional and fpost-transcriptional regulation, protein degradation, subcellular localization, and the recruitment of amplifiers and inhibitors, along with metabolic and microbial factors. These regulatory strategies ensure immune signaling remains adaptable and precise, preventing excessive inflammation. The review also explores the therapeutic potential of targeting PRRs in treating infectious, inflammatory, autoimmune, and malignant diseases, underscoring their importance in advancing immunological research and precision medicine.